| Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments DW Bell, DA Haber, PA Janne, BE Johnson, TJ Lynch, M Meyerson, ... US Patent 12,006,555, 2024 | | 2024 |
| DrugMap: A quantitative pan-cancer analysis of cysteine ligandability M Takahashi, HB Chong, S Zhang, TY Yang, MJ Lazarov, S Harry, ... Cell 187 (10), 2536-2556. e30, 2024 | 6 | 2024 |
| Digital Analysis of Circulating Tumor Cells in Blood Samples DA Haber, R Kapur, M Toner, S Maheswaran, X Hong, DT Miyamoto, ... US Patent App. 18/396,156, 2024 | | 2024 |
| Digital analysis of circulating tumor cells in blood samples DA Haber, R Kapur, M Toner, S Maheswaran, X Hong, DT Miyamoto, ... US Patent 11,898,209, 2024 | 1 | 2024 |
| Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer PJ Saylor, K Otani, R Balza, J Ukleja, H Pleskow, R Fisher, E Kusaka, ... JCO Precision Oncology 8, e2300230, 2024 | | 2024 |
| Deploying blood-based cancer screening DS Micalizzi, LV Sequist, DA Haber Science 383 (6681), 368-370, 2024 | | 2024 |
| Methods relating to circulating tumor cell clusters and the treatment of cancer N Aceto, DA Haber, S Maheswaran US Patent App. 17/863,984, 2024 | | 2024 |
| Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product A Mishra, SB Huang, T Dubash, R Burr, BS Wittner, QE Cunneely, ... bioRxiv, 2024.03. 13.583573, 2024 | | 2024 |
| CDKN1B (p27kip1) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitors. E Horwitz, TD Dubash, A Szabolcs, BS Wittner, J Kreuzer, R Morris, ... bioRxiv, 2024.02. 20.581202, 2024 | | 2024 |
| Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer R Burr, I Leshchiner, CL Costantino, M Blohmer, T Sundaresan, J Cha, ... medRxiv, 2023 | | 2023 |
| Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells TD Dubash, A Bardia, B Chirn, BA Reeves, JA LiCausi, R Burr, BS Wittner, ... Breast Cancer Research and Treatment 201 (1), 43-56, 2023 | 1 | 2023 |
| Method for treating gefitinib resistant cancer DA Haber, DW Bell, JE Settleman, R Sordella, NG Godin-Heymann, ... US Patent App. 17/820,519, 2023 | | 2023 |
| A landscape of response to drug combinations in non-small cell lung cancer NU Nair, P Greninger, X Zhang, AA Friedman, A Amzallag, E Cortez, ... Nature Communications 14 (1), 3830, 2023 | 16 | 2023 |
| DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs H Guo, JA Vuille, BS Wittner, EM Lachtara, Y Hou, M Lin, T Zhao, ... Cell 186 (13), 2765-2782. e28, 2023 | 14 | 2023 |
| A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression JO Brett, TD Dubash, GN Johnson, A Niemierko, V Mariotti, LSL Kim, J Xi, ... JCO Precision Oncology 7, e2200532, 2023 | 6 | 2023 |
| Abstract CT073: Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation TD Dubash, A Bardia, B Chirn, BA Reeves, JA LiCausi, R Burr, BS Wittner, ... Cancer Research 83 (8_Supplement), CT073-CT073, 2023 | | 2023 |
| Mechanisms of genetic predisposition to multifocal lung cancer R Burr, I Leshchiner, CL Costantino, M Blohmer, T Sundaresan, J Cha, ... Cancer Research 83 (7_Supplement), 771-771, 2023 | | 2023 |
| TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state S Matsuda, A Revandkar, TD Dubash, A Ravi, BS Wittner, M Lin, R Morris, ... Cell reports 42 (3), 2023 | 20 | 2023 |
| Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade DB Fox, RY Ebright, X Hong, HC Russell, H Guo, TJ LaSalle, BS Wittner, ... NPJ Precision Oncology 7 (1), 25, 2023 | 5 | 2023 |
| Abstract IA010: Hypomethylation of immune-related loci contribute to prostate tumorigenesis DA Haber, H Guo, BS Wittner, JA Vuille, MS Lawrence, CL Wu, M Toner, ... Cancer Research 83 (2_Supplement_2), IA010-IA010, 2023 | | 2023 |
